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Abstract
Background: Many countries, such as Niger, are considering changing their vaccine vial size presentation and may
want to evaluate the subsequent impact on their supply chains, the series of steps required to get vaccines from
their manufacturers to patients. The measles vaccine is particularly important in Niger, a country prone to measles
outbreaks.
Methods: We developed a detailed discrete event simulation model of the vaccine supply chain representing
every vaccine, storage location, refrigerator, freezer, and transport device (e.g., cold trucks, 4 × 4 trucks, and vaccine
carriers) in the Niger Expanded Programme on Immunization (EPI). Experiments simulated the impact of replacing
the 10-dose measles vial size with 5-dose, 2-dose and 1-dose vial sizes.
Results: Switching from the 10-dose to the 5-dose, 2-dose and 1-dose vial sizes decreased the average availability
of EPI vaccines for arriving patients from 83% to 82%, 81% and 78%, respectively for a 100% target population size.
The switches also changed transport vehicle’s utilization from a mean of 58% (range: 4-164%) to means of 59%
(range: 4-164%), 62% (range: 4-175%), and 67% (range: 5-192%), respectively, between the regional and district
stores, and from a mean of 160% (range: 83-300%) to means of 161% (range: 82-322%), 175% (range: 78-344%),
and 198% (range: 88-402%), respectively, between the district to integrated health centres (IHC). The switch also
changed district level storage utilization from a mean of 65% to means of 64%, 66% and 68% (range for all
scenarios: 3-100%). Finally, accounting for vaccine administration, wastage, and disposal, replacing the 10-dose vial
with the 5 or 1-dose vials would increase the cost per immunized patient from $0.47US to $0.71US and $1.26US,
respectively.
Conclusions: The switch from the 10-dose measles vaccines to smaller vial sizes could overwhelm the capacities of
many storage facilities and transport vehicles as well as increase the cost per vaccinated child.
Keywords: Measles Vaccine, Vaccine Supply Chain, Niger
Background
Many countries, such as Niger, are considering changing
their vaccine vial size presentations, i.e. number of doses
per vial. Single-dose vials reduce contamination risk,
inaccurate dosing, and vaccine wastage, but increase
space requirements, medical waste volume and costs per
dose[1-4]. Countries changing vaccine vial size presenta-
tions in their World Health Organization (WHO)
Expanded Programmes on Immunization (EPI) should
evaluate the subsequent impact on their supply chains,
the series of steps required to get vaccines from their
manufacturers to patients. The measles vaccine is parti-
cularly important in Niger, a country prone to measles
outbreaks[5,6]. In 2003, health officials in Niger reported
50,138 cases and 201 deaths from measles[5]. Providing
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any medium, provided the original work is properly cited.vaccines to children, especially in rural areas, has been
challenging[5,6].
The Vaccine Modelling Initiative (VMI), funded by the
Bill and Melinda Gates Foundation, collaborated with
the Ministry of Health and WHO in Niger and other
partners, to develop a computational model of the
national vaccine supply chain. We developed a model of
the Niger vaccine supply chain representing the flow of
all WHO EPI vaccines from manufacturers, to the cen-
tral storage facility (Niamey), through each subsequent
level of the supply chain, and finally to vaccine recipi-
ents at integrated health centres (IHCs) (i.e., service
delivery level). Using this model, we simulated the repla-
cement of multi-dose measles vaccines with vaccines in
smaller vial sizes to determine the impacts on the supply
chain.
Methods
General Framework
The Highly Extensible Resource for Modelling Supply
Chains (HERMES), a custom-designed, dynamic, dis-
crete event simulation model (DES), is written in the
Python programming language, using features provided
by the SimPy package[7]. This model explicitly simulates
all processes, storage locations, administering locations,
and storage equipment in the Niger vaccine supply
chain.
Niger Vaccine Supply Chain and Data Sources
Figure 1 shows the four levels of the supply chain. Data
to construct the models was collected from the WHO
in Geneva, WHO in Niger, UNICEF, the Niger National
Geographic Institute (NGI), the Niger Ministry of
Health (MOH), the WHO EPI in Niger, and direct field
observations. In 2009, the following data was collected
in-country to begin model development: cold chain
equipment inventory[8]; transportation resources; oper-
ating polices for shipments, storage, and aspects of vac-
cine administration; and patterns of patient arrival.
The number of vaccines administered at the IHCs is a
function of the population demand. The population
demand is estimated using district-level birth registry
data from 2005 (557,381 total newborns across all dis-
tricts) adjusted by an annual growth rate of 1.04% to
2010 (586,880 total newborns across all districts) to
account for population growth[9]. Newborns are distrib-
uted among the 695 IHC sites, and in each of the
immunization sessions each month. Each time a patient
arrives for vaccination at an IHC, he or she receives the
appropriate age-specified (0-11 month, and 12-24
month old children) vaccines, if they are available.
Model Structure
We chose to utilize a DES model because the effects of
changing the measles vaccine vial size may be subtle,
complex, dynamic and not captured by less detailed
representations. For example, changing vial size can
affect the ability of a clinic to fulfil demand and the
amount of open vial wastage, which affects a clinic’s
order sizes, effects that may propagate up the supply
chain.
In HERMES, each vaccine vial is an entity complete
with its own set of relevant characteristics such as vac-
cine antigen type, doses per vial, shelf-life, formulation,
and packaged volume. Each Niger EPI vaccine vial [i.e.,
Bacille Calmette-Guérin tuberculosis (BCG), oral polio
(OPV), measles, yellow fever (YF), tetanus toxoid (TT),
and the diphtheria-tetanus-pertussis-haemophilus influ-
enzae type B-hepatitis B (DTP-HepB-Hib) vaccines] is
represented as an entity. Each vaccine vial entity begins
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Page 2 of 9at the manufacturer and is packaged into a shipping lot
with other vial entities. From there, the entity gets deliv-
ered with the shipping lot to the central store where the
entity is unloaded, repackaged into a smaller lot and
stored in a cold room until it is scheduled for further
shipment. When shipment time comes, depending on its
destination, it will either be loaded into cold trucks des-
tined for regional stores, or 4 × 4 trucks destined for
district stores, where it will be unloaded, repackaged
into a smaller lot and stored in a cold room, refrigerator
or freezer. A district store will use its 4 × 4 truck to col-
lect the entity in its lot whenever its inventory is
depleted by downstream clinics. A clinic will then send
its vaccine carrier to its district store to collect the
entity in its lot when the clinic reaches its re-order
point. At each storage location and in transport vehicle,
an entity has a probability of breakage from mishand-
ling. The entity also has a specified lifetime beyond
which its doses expire.
Based on WHO recommendations, HERMES assumes
that clinics and district stores re-order points are 25% of
their maximum and that orders will account for a 25%
buffer[10]. When cold space is limited, HERMES uses a
balanced allocation scheme wherein complete vaccine
regimens (i.e., all doses required for full immunization)
are prioritized over single antigens, and a ‘first-in-first-
out’ policy is used every time a vaccine is removed from
a storage or transport device. Each simulation represents
a one-year time horizon over which statistics on vacci-
nation rates, stock-outs, vial expiration, and storage and
transport utilization are accumulated.
Each refrigerator maintains a temperature of 2°C to 8°
C and each freezer a temperature of -15°C to -25°C.
Each vaccine’s required temperature profile determines
whether it will be stored in freezer or refrigerator
compartments.
Current vaccine inventory in each cold room, freezer,
refrigerator, or transport device (i.e., the number of vac-
cines currently stored in that device) is equal to the
number of vaccines arriving that day plus the number of
vaccines left over from the previous day minus the num-
ber of vaccines removed (to either be shipped or admi-
nistered).The model does not allow the total vaccine
inventory stored in a refrigerator, freezer, or cold room
to ever exceed the device’s storage capacity.
Open vial wastage occurs when vials are opened but
not all the doses are completely consumed before
expiration (e.g., only two doses used from a five-dose
vial) as detailed by a previously published study and the
WHO’s Multi-Dose Vial Policy (MDVP)[4,11].
Vaccine Specifications
Table 1 lists Niger’s six EPI vaccines[12]
,[13,14]. Infor-
mation from previous studies was used to compute the
cost of contaminated medical waste disposal[15]. The
volumes of the diluents are considered, but only con-
sume space at the IHC locations several hours prior to
vaccine administration.
Niger currently supplies measles vaccines in 10-dose
vials (2.61cm
3 per dose). Our analysis explores the
effects of substituting the measles vaccine dose adminis-
tered at age <1 year from the 10-dose vial with a 5, 2 or
1-dose vaccine presentation.
Supply Chain Performance Metrics
Vaccine availability (percent of children arriving at a
health centre who are able to receive their requested vac-
cine due to vaccine inventory availability) is computed
for each simulation for each vaccine type at each IHC:
Vaccine Availability = (Number of patients receiving
vaccine)÷(Number of patients arriving at an IHC) per
year
Table 1 Niger’s EPI Vaccine Characteristics *Vaccines not included in current EPI schedule
Expanded Programme on
Immunization (EPI) Vaccine
Immunization
schedule
Doses
per
person
Doses
per
vial
Packaged
volume per
dose (cm
3)
Packaged
volume per
diluent (cm
3)
Route of
administration
Preferred
storage
Source
Bacille Calmette-Guerin (BCG) Birth 1 20 1.2 0.7 Intra-dermal Refrigerator [11-13]
Diptheria-tetanus-pertussis-
hepatitis B-haemophilus influenza
type B (DTP-HepB-Hib)
6, 10, 14 weeks 3 1 16.8 None Intra-muscular Refrigerator [11-13]
Yellow Fever (YF) 9 months 1 10 2.5 6.0 Sub-cutaneous Refrigerator [11-13]
Oral Polio Virus (OPV) Birth, 6, 10, 14
weeks
4 20 1.0 None Intra-muscular Freezer [11-13]
Tetanus Toxoid (TT) 1
st contact, 4
weeks, 6
months, 1 year
5 10 3.0 None Intra-muscular Refrigerator [11-13]
Measles (M) 9 months 1 10 2.6 0.5 Sub-cutaneous Refrigerator [11-13]
Measles (M)* 9 months 1 5 5.2 0.5 Sub-cutaneous Refrigerator [11-13]
Measles (M)* 9 months 1 2 13.1 0.5 Sub-cutaneous Refrigerator [11-13]
Measles (M)* 9 months 1 1 26.1 0.5 Sub-cutaneous Refrigerator [11-13]
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Page 3 of 9The transport capacity utilization rate for each trans-
port device (e.g., truck, cold box or vaccine carrier) and
the storage utilization rate for each refrigerator and free-
zer are computed for each simulation run:
Transport Capacity Utilization Rate = Transport
space consumed÷Total available transport space per
shipment
Storage Utilization Rate = Storage space consumed÷-
Total available storage space per refrigerator or freezer
Using input values from Tables 1 and 2, the following
equations are employed to calculate costs of using a sin-
gle versus multi-dose vial (i.e., cost of vaccine dose
administration, wastage, and disposal)[16]. A generally
accepted discounted rate of 3% updated costs to 2011
United States dollars ($US)[17]:
Cost of using single-dose vial = Cost of administering
a dose+Cost of disposal
Cost of using multi-dose vial = Cost of administering
a dose+Cost of wasted doses+Cost of disposal
￿ Cost of administering a dose =( Cost of vac-
cine per dose*Number of doses administered)
+(Cost of an administration syringe*Number of
doses administered)+Cost of the total number of
reconstitution syringes
￿ Cost of wasted doses = Cost of vaccine per
dose*Number of wasted doses
￿ Cost of disposal = Safety box cost per dose
+(Waste disposal cost per kg*(Weight of a vial
+weight of a reconstitution syringe+weight of total
administering syringes))
The price per dose of the 2-dose measles vial size is
unknown. The price per dose of the 5-dose vial is taken
from a previous study which used linear regression ana-
lysis on all available vaccine vial sizes to estimate three
price points[16]. All other vial size prices per dose are
taken from the 2009 WHO Vaccine Volume Calculator
[14].
Each vial size scenario is simulated and averaged over
ten realizations. Due to stochasticity, the number of
arriving patients in each scenario varies slightly across
vial size scenarios.
Sensitivity Analyses
Sensitivity analyses systematically ranged the following
parameters: inventory loss rate (range: 0-2%), shipping
loss rate (range: 0-2%), storage capacity utilization (85-
100%), population demand (static [i.e., number of
patients in a month is fixed based on projected popula-
tion estimates and does not fluctuate from month to
month] versus dynamic monthly distribution [i.e., num-
ber of vaccine recipients in a given month draws from a
Poisson distribution with a mean of (l)]), and percen-
tage of the target population that actually arrives at
clinics to be vaccinated (60-100%).
Model validation consisted of running similar scenar-
ios in a previously published deterministic equation-
based model and observing convergence in results from
both models (Lee BY, et al: Impact of introducing the
pneumococcal and rotavirus vaccines into the routine
immunization programme in Niger, submitted). We also
compared the trends seen in our experiments with those
from other similar field studies in other countries[18].
Table 2 Cost Inputs for Vaccine Variables
Variable Mean Min Max Source
Cost per dose of vaccine ($US)
Measles 10-dose 0.246 - - [13,14]
Measles 5-dose 0.450 0.405 0.495 [16]
Measles 1-dose 0.943 - - [13,14]
Volume per dose of vaccine (cm3)
Measles 10-dose 2.460 2.214 2.706 [13,14]
Measles 5-dose 5.220 4.698 5.742 [13,14]
Measles 1-dose 26.110 23.499 28.721 [13,14]
Weight of vaccines and vaccine accessories (g)
10-dose vial (empty) 3.522 3.169 3.874 [16]
5-dose vial (empty) 2.517 2.265 2.768 [16]
1-dose vial (empty) 1.713 1.542 1.885 [16]
Reconstitution syringe 6.625 5.967 7.293 [16]
Injection syringe 6.625 5.967 7.293 [16]
Cost of medical vaccine accessories (2009 $US) and waste disposal (2004 $US) adjusted to 2010 $US [17]
Waste disposal cost per kg 6.850 2.066 10.830 [15]
Waste disposal cost per g 0.0069 0.0021 0.0108 [15]
Injection syringe 0.070 - - [14]
Reconstitution syringe 0.060 - - [14]
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Sensitivity analyses demonstrated that varying the
patient demand (static versus dynamic), shipping and
inventory loss, and storage capacity utilization did not
notably affect the pattern of results. Varying the target
population that actually arrived at a clinic to be vacci-
nated had noteworthy effects on vaccine availability,
transport and storage utilization. Therefore, the follow-
ing results report from scenarios representing 1% inven-
tory and shipping loss, 100% capacity utilization, and
dynamic monthly demand for target population sizes of
100%, 80% and 60%.
Overall Impact
Our model results suggest that the larger packaged
volumes per dose of the 1-dose, 2-dose, and 5-dose
measles vial sizes reduce vaccine availability at IHCs.
Smaller vial sizes create greater bottlenecks in the
already constrained region-to-district and district-to-
IHC transportation devices. Moreover, while larger vial
sizes result in more wasted doses, their lower price per
dose provides relative cost savings. Additionally, the
increased number and volume of vials and injection
accessories (e.g., injection and reconstitution syringes)
associated with smaller vial sizes results in substantial
increases in waste disposal costs.
Impact on Vaccine Administration
Switching from the 10-dose to the 5-dose, 2-dose and 1-
dose measles vaccine vial size decreased the percent of
arriving patients receiving vaccines (vaccine availability)
from 90%, (58,482 of 583,575 measles vaccination
opportunities being missed), to 87% (75,116 of 583,477
missed vaccination opportunities), 86% (84,307 of
583,722 missed measles vaccination opportunities) and
80% (117,167 of 583,264 missed measles vaccination
opportunities), respectively, across the entire country.
Table 3 lists vaccine availabilities for other EPI vac-
cines across 60%, 80% and 100% target population sizes.
Not only do the smaller vial size scenarios affect avail-
ability of the measles vaccine, but the average availability
across other current EPI vaccines also decreased slightly
following the switch.
Impact on Vaccine Transport
Figure 2 shows frequency histograms for transport capa-
city utilization between the region and district, and dis-
trict and IHC levels across different vial size scenarios.
In the first column, each bar in a histogram represents
the number of transport vehicles along a route experien-
cing a certain percentage of capacity utilization. For
example, in the first panel, for all vial size scenarios, 5
of the 7 central-to-region transport routes outside the
Table 3 Vaccine Availability across Measles Vaccine Vial Size Scenarios and Target Population Sizes
Measles Vaccine Vial Size Scenario 10-doses per
vial
5-doses per
vial
2-doses per
vial
1-doses per
vial
100% Target Population Size
Bacille Calmette-Guerin Tuberculosis (BCG) 79% 79% 78% 76%
Diptheria-tetanus-pertussis-hepatitis B-haemophilus influenza type B (DTP-
HepB-Hib)
84% 84% 82% 80%
Measles 90% 87% 86% 80%
Oral polio (OPV) 80% 80% 78% 76%
Tetanus toxoid (TT) 84% 84% 83% 80%
Yellow fever (YF) 79% 79% 78% 76%
80% Target Population Size
BCG 84% 85% 85% 84%
DTP-HepB-Hib 86% 86% 86% 84%
Measles 94% 92% 89% 84%
OPV 80% 80% 80% 79%
TT 86% 86% 86% 84%
YF 84% 85% 85% 84%
60% Target Population Size
BCG 81% 81% 81% 80%
DTP-HepB-Hib 91% 91% 91% 89%
Measles 93% 91% 91% 90%
OPV 82% 82% 82% 82%
TT 90% 90% 90% 89%
YF 81% 81% 81% 80%
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capacity. In this figure, any transport capacity utilization
exceeding 100% is the demand requested utilization
from a downstream location, while the actual utilization
of the vehicle is limited to 100%. For example, if a clinic
needs 100 vials but their transport device can only carry
50, their transport device will be overfilled, its transport
utilization will be 200%, but it can send at most 100%
(or 50 of 100 vials). Those portions of the orders above
100% go un-served and are added to the next shipment.
There was enough cold transport capacity for vaccine
shipments from the central store to the regional stores
in the two shipping loops for all vial size scenarios only
changing the median utilization from 66% for the two
cold trucks which distribute vaccines to 7 regional
stores, to 66%, 71% and 77% for the 5-dose, 2-dose and
1-dose vial sizes, respectively. However, the 7 district
stores in the region that procure their own vaccines in 4
× 4 trucks consistently experienced overfill from a med-
ian across transport routes of 68% transport capacity
utilization (range: 32-615%) for the 10-dose vial size sce-
nario, to 74% (range: 32-616%), 80% (range: 32-659%)
and 90% (range: 32-720%) for the 5-dose, 2-dose and 1-
dose vial size scenario, respectively, resulting in many
necessary vaccines in excess of available transport capa-
city not being delivered.
Similarly, the bottleneck in transport continues from
regional to district level stores, wherein with the excep-
tion of one district store that has no cold storage capa-
city, the median 4 × 4 truck capacity utilization across
transport routes changed from 53% (4-164%) in the 10-
dose vial size scenario to 55% (range: 4-164%), 56%
(range: 5-175%) and 56% (5-192%), respectively.
Bottlenecks in transport continue to have an impact
from district to IHCs wherein the median vaccine car-
rier capacity utilization across transport routes changed
from 149% (range: 83-300%) in the 10-dose vial size sce-
nario to 154% (range: 82-322%), 168% (range: 78-344%)
and 189% (range: 84-402%) for the 5-dose, 2-dose and
1-dose vial size scenarios, respectively. Reducing the tar-
get population to 80% and 60% reduces the median uti-
lizations of cold trucks by up to 20% from the previous
scenario, 4 × 4 trucks (central to regional) by up to
18%, 4 × 4 trucks (region to district) by up to 10%, and
vaccine carriers by up to 20%, respectively.
Impact on Vaccine Storage
Figure 3 shows frequency histograms of the storage
capacity utilization at the regional, district, and IHC
stores across vial size scenarios. While cold room capa-
city utilization at the central level did increase for some
scenarios from 65% in the 10-dose vial size scenario to
65%, 70% and 76%, for the 5-dose, 2-dose and 1-dose
vial size scenarios, respectively, there was ample room
for future vaccine introductions or storage of other tem-
perature sensitive products.
The regional level also had enough capacity to accom-
modate the added volume from the smaller vial sizes,
only changing the median capacity utilization for some
scenarios across regional stores from 12% (range: 1-27%)
in the 10-dose vial size scenario to 15% (range: 1-27%),
16% (range: 1-29%), and 17% (range: 1-33%) in the 5-
dose, 2-dose, and 1-dose vial size scenarios, respectively.
Storage capacity bottlenecks first emerged at the dis-
trict level with median district level refrigerator utiliza-
tion across district stores changing slightly for some
scenarios from 63% in the 10-dose vial size scenario to
63%, 67%, and 73% (range for all scenarios: 3-100%).
The number of district stores exceeding 80% of their
a v a i l a b l er e f r i g e r a t o rc a p a c i t yc h a n g e df o rs o m es c e n a r -
ios from 17 to 16, 17 and 18 stores out of 42, many of
which exceeded even 95% of their available storage
space for the 5-dose, 2-dose and 1-dose vial sizes,
respectively.
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Page 6 of 9Given the persistent district level storage and trans-
port bottlenecks with decreasing vial size, fewer vaccines
were able to reach the IHC level and the median storage
capacity utilization across IHCs did not change substan-
tially from 33% (range: 3-99%) for the 5-dose vial size,
34% (range: 0-98%) for the 2-dose vial size, and 36%
(range: 0-97%) for the 1-dose vial size compared to 34%
(range: 4-98%) in the 10-dose vial size scenario. More-
over, the number of IHC stores exceeding 80% of their
storage capacity decreased slightly in some scenarios
from 67 to 61, 67 and 87 of 695 stores for the 5-dose,
2-dose and 1-dose vial sizes, respectively. Reducing the
target population from 100% to 80% reduces the median
storage capacity utilization across levels by 0-4% and
from 80% to 60% by 5-20%.
Impact on Vaccine Supply Chain Costs
Despite reductions in open vial waste with the 5-dose,
2-dose and 1-dose vial sizes compared to the 10-dose
vial size, the number of doses saved was outweighed by
the costs associated with the increasing price per dose
and cost of waste disposal as vial sizes decreased. The
number of wasted doses of the measles vaccine
decreased from 1,279,450 for the 10-dose vial size to
442,398, 96,357 and 0 for the 5-dose, 2-dose and 1-dose
vial sizes, respectively. However, the total costs of
wasted doses from open vial waste increased from
$33,391US for the 10-dose vials ($0.25US/dose) to
$42,205US (range: $38,046US-$46,894US) for the 5-dose
vials ($0.48US/dose, range: $0.43US-$0.53US) per year
across Niger on account of the increasing cost per dose
with decreasing vial size. The cost of the 2-dose vial was
unknown and the 1-dose vial size ($0.94US/dose) pro-
duced no open vial waste. Similarly, as the vial size
decreased, the cost of vaccine administration more than
doubled from $179,779US in the 10-dose vial size sce-
nario to $287,131US (range: $263,194US-$314,124US)
and more than tripled to $586,214US in the 5-dose and
1-dose vial sizes, respectively. Finally, the increased
volume of vials and injection material per dose with
smaller vial sizes resulted in increased costs of contami-
nated waste disposal from $31,588US to $33,275US and
$55,025US. All three cost components combined trans-
late to a total cost increase from $244,759US to
$362,611US ($334,515US-$403,279US) and $586,214US,
or to an increase in the cost per injection from $0.47US
in the 10-dose vial size scenario to $0.71US ($0.66US-
$0.77US) and $1.26US in the 5-dose and 1-dose vial size
scenarios.
Given that there were fewer administered doses with
the 5 and 1-dose vial size scenarios, these costs would
likely increase if there were enough storage and trans-
port capacity to achieve baseline measles vaccine supply
ratios or higher.
Discussion
Results suggest that while selecting smaller vial sizes
substantially reduces open vial waste, current storage
and transport resources at the district and IHC levels of
the Niger vaccine supply chain are pushed to their capa-
city, which results in lower vaccine availability of smaller
vial sizes at the IHC level. The increased space require-
ment associated with the smaller vial sizes could also
limit the supply chain’s flexibility to respond to sudden
changes that would require extra capacity (e.g., vehicle
breakdown, refrigerator failure, etc.) or future antici-
pated increases in vaccine throughput from the intro-
duction of new and under-utilized vaccines. Moreover,
decreasing the vial size would increase the cost of the
vaccine per dose and the total volume of vials and safe
injection equipment in the supply chain, thereby
increasing the costs of vaccine administration and waste
disposal, which far outweigh the costs saved from the
decrease in wasted doses.
Several noteworthy effects resulted when we reduced
the target population to 80% and 60% of total EPI-eligi-
ble children: 1) smaller session sizes were associated
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Single-dose Measles Vaccine Presentations.
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Page 7 of 9with higher vaccine wastage, and 2) the wastage rate
varied across vaccine types (i.e., liquid versus lyophi-
lized), and across vial sizes (i.e., 1, 5, 10 and 20 doses
per vial). For example, OPV, DTP-HepB-Hib, and TT
had lower wastage than measles, BCG and YF because
according to the WHO’s MDVP, these liquid vaccines
c a nb ek e p tu pt o4w e e k sa f t e ro p e n i n g [ 1 1 ] .T h es m a l -
ler vial sizes experienced higher wastage than the larger
vial sizes, particularly for smaller session sizes. These
are important findings that have also been reported in
other field programme evaluations in similar settings,
and suggest tailoring vial size selections to anticipated
session sizes[18]. For example, 1 and 2-dose vials can be
used efficiently for birth doses, whereas 10 and 20-dose
vials would be better suited for mass vaccination cam-
paigns or clinics with larger volumes of patients. This
may require customizing re-order policies for specific
regions, districts, or clinics where demand for vaccines
is highly variable. Scaling up orders based on global esti-
mates of vaccine-specific open vial waste for the whole
supply chain, especially ones with high population varia-
bility may lead to over or under-ordering vaccines in
some locations.
Our findings highlight the importance of considering
the effects on existing supply chain resources when
changing the presentations of vaccines in a country’s
EPI. Introducing a new vaccine presentation into a sup-
ply chain with limited resources can not only affect the
supply of that vaccine, but also of all other vaccines in
the EPI, which could ultimately hinder important infec-
tious disease control efforts. Simulations of vaccine dis-
tribution through supply chains prior to any change in
the EPI vaccines or to the structure of the supply chain
itself can help pinpoint series of locations along the
chain where bottlenecks, stock-outs, or overstocking
may occur. These evaluations can then inform public
health decision makers and logisticians on where the
addition of new resources (e.g., refrigerators, freezers,
trucks, etc.) would be most beneficial.
Additionally, our findings also illustrate the impor-
tance of considering medical waste when introducing a
new vaccine presentation or vaccine technology. Impro-
perly disposing of waste can result in harmful exposure
to blood-borne pathogens. The costs of effective systems
to safely remove contaminated medical waste and pre-
vent infection often include costs for separating, sorting,
treating, and transporting different kinds of waste pro-
ducts to disposal facilities where they can be either bur-
ied or incinerated[19].
However, rather than discourage the use of single-
dose vaccine presentations, our findings simply help
identify some of the programmatic and economic
repercussions of switching from 10-dose to 5-dose, 2-
dose or 1-dose vaccine presentations. Smaller vial size
presentations offer certain benefits not accounted for
by our study. The 1-dose presentation may allow for
more consistent dose-size administration, reduce the
risk of cross-contamination from repeated entry by
reconstitution syringes and injection syringes for
administrations, and provide more convenience to
health care workers who would otherwise have to keep
track of the number and volume of doses they with-
draw. Eliminating open vial wastage may also alleviate
the need for policies to plan when and when not to
open new vials in response to arriving patients in
order to minimize open vial wastage.
Our study illustrates how models can be applied in
different scenarios to identify the effects of decisions
not immediately apparent. Models have been com-
monly used for decision making in many other indus-
tries, such as manufacturing[20], meteorology[21],
transportation[22], aerospace[23], finance[24], and
sports and rehabilitation[25]. Conversely, their uses in
public health have been relatively less extensive[26-28].
Of late, models in public health have assisted
responses to the spread of infectious disease (e.g., the
2009 H1N1 influenza pandemic) and health-care asso-
ciated infections[29-33], but much of their potential
applications remain untapped.
Limitations
Given that models are by definition, simplified represen-
tations of real life, they cannot capture every potential
factor, event, or outcome[34,35]. Additionally, the data
parameters included in our model are collected up to
2010 and may not represent future changes that may
occur in the Niger vaccine supply chain. Due to the
paucity of available data, the actual daily patient demand
may vary from our estimated demand. Furthermore,
developing our model involved substantial data collec-
tion including obtaining records from and conducting
interviews at different locations in and out-of-country
and came from a wide variety of sources. Thus, para-
meter values may vary in accuracy and reliability.
Despite these limitations, sensitivity analyses demon-
strated that model outcomes are robust under a wide
variety of circumstances.
Conclusions
While smaller vial sizes of the measles vaccine lead to
decreases in open vial waste, the space utilization of sev-
eral storage sites and transport routes in the Niger vac-
cine supply chain are insufficient to accommodate their
higher volumes per dose, which result in lower vaccine
availability for arriving patients. Moreover, at higher
prices per dose, the costs of wasted doses and
Assi et al. BMC Public Health 2011, 11:425
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Page 8 of 9contaminated waste disposal ultimately outweigh the
benefits provided by reducing or eliminating open vial
waste.
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